AU2003273994A1 - Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43) - Google Patents

Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)

Info

Publication number
AU2003273994A1
AU2003273994A1 AU2003273994A AU2003273994A AU2003273994A1 AU 2003273994 A1 AU2003273994 A1 AU 2003273994A1 AU 2003273994 A AU2003273994 A AU 2003273994A AU 2003273994 A AU2003273994 A AU 2003273994A AU 2003273994 A1 AU2003273994 A1 AU 2003273994A1
Authority
AU
Australia
Prior art keywords
gpr43
therapeutics
diagnostics
protein
diseases associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003273994A
Other versions
AU2003273994A8 (en
Inventor
Ulf Bruggemeier
Stefan Golz
Holger Summer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of AU2003273994A8 publication Critical patent/AU2003273994A8/en
Publication of AU2003273994A1 publication Critical patent/AU2003273994A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
AU2003273994A 2002-10-25 2003-10-13 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43) Abandoned AU2003273994A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02023796 2002-10-25
EP02023796.2 2002-10-25
PCT/EP2003/011314 WO2004038405A2 (en) 2002-10-25 2003-10-13 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)

Publications (2)

Publication Number Publication Date
AU2003273994A8 AU2003273994A8 (en) 2004-05-13
AU2003273994A1 true AU2003273994A1 (en) 2004-05-13

Family

ID=32116227

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003273994A Abandoned AU2003273994A1 (en) 2002-10-25 2003-10-13 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)

Country Status (2)

Country Link
AU (1) AU2003273994A1 (en)
WO (1) WO2004038405A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1797435A2 (en) 2004-09-22 2007-06-20 Arena Pharmaceuticals, Inc. Gpr43 and modulators thereof for the treatment of metabolic-related disorders
EP2414829A1 (en) 2009-04-01 2012-02-08 Galapagos N.V. Methods and means for treatment of osteoarthritis
CA2779088A1 (en) 2009-11-16 2011-05-19 Mellitech [1,5]-diazocin derivatives
WO2014011926A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
KR101656662B1 (en) * 2014-11-18 2016-09-12 한국생명공학연구원 Pharmaceutical composition containing 2-Oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide derivatives for prevention or treatment of metabolic disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910430A (en) * 1997-01-24 1999-06-08 Smithkline Beecham Corporation Isolated nucleic acid encoding G-protein coupled receptor (HTADX50)
US20020077287A1 (en) * 1998-09-11 2002-06-20 Ruben Steven M. 28 human secreted proteins
AU760274B2 (en) * 1997-09-19 2003-05-08 Genaera Corporation Asthma associated factors as targets for treating atopic allergies including asthma and related disorders

Also Published As

Publication number Publication date
WO2004038405A3 (en) 2004-09-30
WO2004038405A2 (en) 2004-05-06
AU2003273994A8 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
AU2003214072A1 (en) Diagnostics and therapeutics for diseases associated with the n-formyl peptide receptor 1 (fpr 1)
AU2003273994A1 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
AU2003240589A1 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 4 (gpr4)
AU2003229767A1 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 9(ccr9)
AU2003267443A1 (en) Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)
AU2003240720A1 (en) Diagnostics and therapeutics for diseases associated with somatostatin receptor 5 (sstr5)
AU2003205627A1 (en) Diagnostics and therapeutics for diseases associated with gpr72
AU2003240639A1 (en) Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 3 (avpr3)
AU2003227751A1 (en) Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 1 (avpr1)
AU2003206749A1 (en) Diagnostics and therapeutics for diseases associated with the gpr65 receptor
AU2003216866A1 (en) Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 2 (npff2)
AU2003276106A1 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)
AU2003276097A1 (en) Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 42 (gpr42)
AU2003240721A1 (en) Diagnostics and therapeutics for diseases associated with somatostatin receptor 4(sstr4)
AU2003229753A1 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8)
AU2003229736A1 (en) Diagnostics and therapeutics for diseases associated with neurotensin receptor 1 (nt1)
AU2003274005A1 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 6 (gpr6)
AU2003219030A1 (en) Diagnostics and therapeutics for diseases associated with human g protein-coupled orphan receptor 21 (gpr21)
AU2003301892A1 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 3 (gpr3)
AU2003250165A1 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 19 (gpr19)
AU2003210382A1 (en) Diagnostic for diseases associated with g-protein coupled receptor 105 (gpr105)
AU2003250221A1 (en) Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 6(cxcr6)
AU2003218638A1 (en) Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1)
AU2003227064A1 (en) Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 1 (npff1)
AU2003246726A1 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 45 (gpr45)

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase